Zimbabwe’s Ministry of Health and Child Care has issued a public notice recalling two specific batches of the hypertension medication Nifedipine. The recall, announced on June 1, affects 10mg tablets manufactured by Remedica Ltd. and was initiated following quality control monitoring by the Medicines Control Authority of Zimbabwe (MCAZ).
The affected products are Nifedipine 10mg tablets from batches numbered 112033 and 117367. Nifedipine is a medication prescribed for the treatment of high blood pressure and to manage angina, a condition that causes chest pain.
In the notice, the ministry detailed the reasons for the action, stating the recall was a precautionary measure after the MCAZ, the national drug regulatory body, identified quality concerns during routine market surveillance. The specific nature of the quality issues was not detailed in the public announcement.
The Ministry of Health and Child Care has provided clear instructions for healthcare providers and the public. “All wholesalers, dispensing doctors, retail pharmacies, and hospitals are directed to quarantine all the remaining stock of the above batches with immediate effect,” the statement read.
Patients who may be in possession of Nifedipine from the recalled batches have been advised not to use the product and to contact their doctor or pharmacist for guidance on how to proceed and to arrange for alternative medication.
The MCAZ is responsible for protecting public health by ensuring that all medicines, allied substances, and medical devices in Zimbabwe are safe, effective, and of good quality. The authority conducts regular post-market surveillance to monitor the performance of medical products available to consumers.
Remedica Ltd., the manufacturer, is a pharmaceutical company based in Cyprus. There has been no public statement from the company regarding the recall at this time. The Ministry of Health and Child Care has not reported any adverse health events linked to the recalled batches.
 from Remedica Ltd. due to MCAZ-identified quality concerns. Patients should consult doctors.){kind=link}